British pharma giant GSK reports a Q3 loss due to Zantac cancer lawsuits—but CEO Emma Walmsley remains optimistic on delivering 2024 guidance

[#item_full_content]

Leave a Reply

Your email address will not be published. Required fields are marked *

X